| Revenue growth | FY26: 6.9% YoY; Q4FY26: 6.1% YoY. |
|---|---|
| Margins | Structural improvement; EBITDA margin expanded ~560 bps from FY24 to FY26. |
| Demand visibility | Broad-based momentum across key global regions like Europe and LATAM. |
| Management confidence | High; confident in high single-digit growth for FY27. |
Growth
FY26 revenue grew 6.9% to ₹25,518 Mn; EBITDA surged 19.6% to ₹8,577 Mn with margins at 33.6%.
Outlook
FY27 guidance: high single-digit revenue growth and 30%+ margins. Total capacity to double to 2,690 KL by FY28.
Risks
GPL business de-grew 4.9%; higher working capital at 199 days; tariff and supply chain uncertainty noted.
Earnings Call filed with BSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,380.00
- Market cap
- ₹16,942 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 28.1×Sector 47.4×
- Promoter holding
- 74.87%+0.00% QoQ
- FII holding
- 5.54%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
- Value
- ₹0.90 Cr
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Merger & Restructuring Worth ₹9.12 Cr
Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.
- Value
- ₹9.12 Cr
Alivus Life Sciences Business Update
Alivus Life Sciences submitted its Business Responsibility & Sustainability Report for FY 2025-26, detailing operational metrics, employee statistics, and sustainability performance.
Alivus Life Sciences Annual Report
Alivus Life Sciences Limited has filed its Integrated Annual Report for FY 2025-26 in compliance with Regulation 34(1) of SEBI Listing Regulations.
Alivus Life Sciences Annual General Meeting
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The company fixed September 1, 2026, as the record date for a Rs. 5.00 dividend.